Dr Neeraj Agarwal presents results from the phase 3 TALAPRO-3 trial evaluating talazoparib in combination with enzalutamide in patients with metastatic castration-sensitive prostate cancer harbouring homologous recombination repair gene alterations.

The interview highlights how the addition of talazoparib to standard enzalutamide significantly improves radiographic progression-free survival compared with enzalutamide alone.

The benefit is observed across both BRCA-mutated and non-BRCA subgroups, with the greatest magnitude of effect seen in patients with BRCA alterations. While overall survival data remain immature, there is a positive trend favouring the combination.

The safety profile is consistent with prior experience, with haematologic adverse events such as anaemia being the most common, and generally manageable with dose modifications.

Overall, these findings support talazoparib plus enzalutamide as a clinically meaningful treatment option in patients with HRR-deficient metastatic castration-sensitive prostate cancer, offering improved disease control in the first-line setting.